Burning Rock Biotech (BNR) Capital Leases (2019 - 2020)

Burning Rock Biotech (BNR) recorded quarterly Capital Leases of $116000.0 in Q3 2020, down 62.21% quarter-over-quarter from $307000.0 in Q2 2020.

Burning Rock Biotech (BNR) Capital Leases (2019 - 2020) Analysis & Trends

Burning Rock Biotech's Capital Leases history runs 2 years deep, the most recent figure standing at $116000.0 for Q3 2020.

In Q3 2020, Capital Leases changed N/A year-over-year to $116000.0; the TTM figure through Sep 2020 stood at $116000.0 (changed N/A YoY), while the FY2019 annual figure was $683297.8, changed N/A from the prior year.
Capital Leases was $116000.0 for Q3 2020 at Burning Rock Biotech, down from $307000.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $683297.8 in Q4 2019 to a low of $116000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	30,529.42 Bn	30,528.96 Bn	1.11 Bn
2	Thermo Fisher Scientific	183.75 Bn	180.50 Bn	7.74 Bn
3	Danaher	133.13 Bn	127.43 Bn	3.59 Bn
4	Idexx Laboratories	46.14 Bn	45.94 Bn	722.74 Mn
5	Agilent Technologies	38.20 Bn	36.39 Bn	990.00 Mn
6	Natera	31.50 Bn	30.40 Bn	696.04 Mn
7	Iqvia Holdings	31.34 Bn	29.36 Bn	1.36 Bn
8	Illumina	24.51 Bn	23.36 Bn	721.00 Mn
9	Mettler Toledo International	23.53 Bn	23.47 Bn	555.82 Mn
10	Burning Rock Biotech	20.64 Mn	-47.19 Mn	14.10 Mn

Download Data